Ocular Therapeutix Adds $6M to C Round

Xconomy Boston — 

Ocular Therapeutix, a Bedford, MA-based developer of therapies for the eye, has brought in an additional $6 million for its Series C round, which now totals $21 million, company co-founder and CEO Amar Sawhney confirmed via e-mail today. The SEC posted a record of the financing on its website today. The company, previously known as I-Therapeutix, announced the previous $15 million close of its third round led by Polaris Venture Partners of Waltham, MA in June 2009. Ocular is advancing hydrogel technology for protecting the eye after ophthalmic surgeries and for delivering drugs to the eye.